NCT05310487View on ClinicalTrials.gov

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

October 3, 2023

Study Completion Date

October 22, 2023

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

162

The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B

OTHER

Placebo

an intervention that appearance is the same as 162, but contains no active ingredients

Trial Locations (1)

Unknown

Nucleus Network Pty Ltd, Melbourne

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Yangshengtang Co., Ltd

INDUSTRY